GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » Market Cap

Xenon Pharmaceuticals (Xenon Pharmaceuticals) Market Cap : $2,874.61 Mil (As of Jun. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Xenon Pharmaceuticals's share price for the quarter that ended in Mar. 2024 was $43.05. Xenon Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 75.46 Mil. Therefore, Xenon Pharmaceuticals's market cap for the quarter that ended in Mar. 2024 was $3,248.54 Mil.

Xenon Pharmaceuticals's quarterly market cap increased from Sep. 2023 ($2,220.48 Mil) to Dec. 2023 ($3,471.59 Mil) but then declined from Dec. 2023 ($3,471.59 Mil) to Mar. 2024 ($3,248.54 Mil).

Xenon Pharmaceuticals's annual market cap increased from Dec. 2021 ($1,613.07 Mil) to Dec. 2022 ($2,467.83 Mil) and increased from Dec. 2022 ($2,467.83 Mil) to Dec. 2023 ($3,471.59 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Xenon Pharmaceuticals's Enterprise Value for Today is $2,257.13 Mil.


Xenon Pharmaceuticals Market Cap Historical Data

The historical data trend for Xenon Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals Market Cap Chart

Xenon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 368.90 538.49 1,613.07 2,467.83 3,471.59

Xenon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,258.60 2,453.15 2,220.48 3,471.59 3,248.54

Competitive Comparison of Xenon Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Xenon Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Market Cap falls into.



Xenon Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Xenon Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$46.06*75.371
=$3,471.59

Xenon Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$43.05*75.4597
=$3,248.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenon Pharmaceuticals  (NAS:XENE) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Xenon Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Executives
Gary Patou director
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover director SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Simon N. Pimstone director 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Ian Mortimer director, officer: PRESIDENT & CEO C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney officer: Chief Medical Officer 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio officer: Chief Legal Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Sherry Aulin officer: Chief Financial Officer 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Sherrington Robin officer: SVP Bus. & Corp. Development C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
James R. Empfield officer: SVP, Drug Discovery 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von officer: Chief Commercial Officer 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W

Xenon Pharmaceuticals (Xenon Pharmaceuticals) Headlines

From GuruFocus

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023

By Stock market mentor Stock market mentor 01-09-2023